The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Application:
FC
Recommended Usage:
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is 20 µl per million cells or 20 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen tissue sections.
Application References:
1. Mollinedo, F., et al., 1997. Clin. and Diag. lab. Immunol. 4:229. 2. Cao, L., et al., 1997. Immunobiology 197(1):70. 3. Amiot, M., 1990. J. Immunol. 145:4322. 4. Vanherberghen, B., et al., 2004. Proc Natl Acad Sci U S A. 101(48):16873.
Human peripheral blood lymphocytes stained with HI29 PE
Description:
CD53 is a 35-42 kD type III tetraspan membrane protein. It is expressed on all leukocytes, but not on platelets or erythrocytes. CD53 is thought to be involved in signal transduction. It has been shown to interact with a number of proteins including IL-4, CD20, CD2, CD9, IL-2, VLA-4, and CD4. Cross-linking of CD53 promotes B cell activation. The CD53 antigen is highly glycosylated and treatment with endoglycosidase F reduces the apparent molecular weight of this protein by approximately 25 kD. The HI29 antibody has been shown to be useful for flow cytometry, and immunohistochemistry (frozen).
Hematopoietic cells including neutrophils, monocytes, B cells, T cells (single positive thymocytes and peripheral T cells), and eosinophils. Not expressed on platelets, erythrocytes, and non-hematopoietic cells
Function:
Signal transduction, cross-linking on B cells causes activation
Modification:
Heavily glycosylated, treatment with endoglycosidase F reduces apparent molecular weight by 25 kD
1. Amiot, M. 1990. J. Immunol. 145:4322. 2. Angelisova, P., et al., 1990. Immunogenetics 32:281. 3. Olweus, J., et al., 1993. J. Immunol. 153:4997. 4. Leukocyte Typing IV. Knapp, W., et al., (Eds), Oxford University Press (1989)
